Recruiting

Advanced non-small cell lung cancer, Cancer

Bayer Identifier:

22913

ClinicalTrials.gov Identifier:

NCT06761976

EudraCT Number:

Not Available

EU CT Number:

Not Available

Expanded access to provide BAY2927088 for the treatment of locally advanced or metastatic NSCLC with HER2 mutation

Trial purpose

The purpose of this Expanded Access Program (EAP) is to allow patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option, to receive BAY2927088.

Key Participants Requirements

Sex

All

Age

18 Years

Trial summary

Enrollment Goal

N/A

Trial Dates

null - Today

Phase

N/A

Could I Receive a placebo

Products

BAY2927088

Accepts Healthy Volunteer

N/A

Trial design

Single Patient Expanded Access Use of BAY2927088 for the Treatment of Locally Advanced or Metastatic NSCLC with HER2 mutation

Trial Type

Expanded Access

Intervention Type

Drug

Trial Purpose

Treatment

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here for access to information about the study and about Bayer’s transparency standards.